Brief Communication

Residual tumor cells are unique cellular targets in glioblastoma†

  1. Martin Glas MD1,2,*,
  2. Barbara H. Rath1,
  3. Matthias Simon MD3,
  4. Roman Reinartz1,
  5. Anja Schramme PhD1,
  6. Daniel Trageser PhD1,
  7. Ramona Eisenreich1,
  8. Anke Leinhaas1,
  9. Mihaela Keller1,
  10. Hans-Ulrich Schildhaus MD4,
  11. Stephan Garbe PhD5,
  12. Barbara Steinfarz1,
  13. Torsten Pietsch MD6,
  14. Dennis A. Steindler PhD7,
  15. Johannes Schramm MD3,
  16. Ulrich Herrlinger MD2,
  17. Oliver Brüstle MD1,
  18. Björn Scheffler MD1,*

Article first published online: 6 APR 2010

DOI: 10.1002/ana.22036

Issue

Annals of Neurology

Annals of Neurology

Volume 68, Issue 2, pages 264–269, August 2010

Additional Information

How to Cite

Glas, M., Rath, B. H., Simon, M., Reinartz, R., Schramme, A., Trageser, D., Eisenreich, R., Leinhaas, A., Keller, M., Schildhaus, H.-U., Garbe, S., Steinfarz, B., Pietsch, T., Steindler, D. A., Schramm, J., Herrlinger, U., Brüstle, O. and Scheffler, B. (2010), Residual tumor cells are unique cellular targets in glioblastoma. Ann Neurol., 68: 264–269. doi: 10.1002/ana.22036

Author Information

  1. 1

    Institute of Reconstructive Neurobiology, University of Bonn Medical Center, Bonn, Germany

  2. 2

    Clinical Neurooncology Unit, Department of Neurology, University of Bonn Medical Center, Bonn, Germany

  3. 3

    Department of Neurosurgery, University of Bonn Medical Center, Bonn, Germany

  4. 4

    Department of Pathology, University of Bonn Medical Center, Bonn, Germany

  5. 5

    Department of Radiology, University of Bonn Medical Center, Bonn, Germany

  6. 6

    Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany

  7. 7

    Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL

*Clinical Neurooncology Unit, Department of Neurology

  1. †

    Auxiliary data, figures, tables, and an extended Subjects and Methods section can be found in the online version of this article.

Publication History

  1. Issue published online: 2 AUG 2010
  2. Article first published online: 6 APR 2010
  3. Manuscript Accepted: 18 MAR 2010
  4. Manuscript Revised: 12 MAR 2010
  5. Manuscript Received: 28 AUG 2009

Funded by

  • BONFOR program grant of the Medical Faculty of the University of Bonn
  • NIH (National Institute of Neurological Disorders and Stroke. Grant Number: NS055165
  • McKnight Brain Institute of the University of Florida
  • Lichtenberg program of the Volkswagen Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (811K)

Abstract

Residual tumor cells remain beyond the margins of every glioblastoma (GBM) resection. Their resistance to postsurgical therapy is considered a major driving force of mortality, but their biology remains largely uncharacterized. In this study, residual tumor cells were derived via experimental biopsy of the resection margin after standard neurosurgery for direct comparison with samples from the routinely resected tumor tissue. In vitro analysis of proliferation, invasion, stem cell qualities, GBM-typical antigens, genotypes, and in vitro drug and irradiation challenge studies revealed these cells as unique entities. Our findings suggest a need for characterization of residual tumor cells to optimize diagnosis and treatment of GBM. ANN NEUROL 2010;68:264–269

View Full Article with Supporting Information (HTML) Get PDF (811K)